Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04047862 · ClinicalTrials.gov registry record · Phase 1
Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors
A Phase 1 study, sponsored by BeiGene.
- Completed
- Registry status
- Phase 1
- Development phase
- 446
- Enrollment target
NCT04047862 is a Phase 1 study that has completed, run by BeiGene. The registered enrollment target is 446 participants.
The verdict
NCT04047862, a Phase 1 study, has completed, sponsored by BeiGene.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 446 participants
- Enrollment target
Study Summary
The primary objectives of this study were: to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217 (known as ociperlimab) in combination with tislelizumab in participants with advanced solid tumors in phase 1. Primary objective of Phase 1b was to assess overall response rate (ORR) determined by Investigator per Response Evaluation Criteria in Solid Tumors (RECIST) version (v).1.1 for patients in each dose-expansion cohort.
Interventions
- DRUG Pemetrexed
- DRUG Tislelizumab
- DRUG Paclitaxel
- DRUG Nab paclitaxel
- DRUG Ociperlimab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 446 participants |
| Start Date | 2019-08-15 |
| Est. Completion | 2024-08-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04047862
The ClinicalTrials.gov registry entry for NCT04047862 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 446 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is BeiGene, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Pemetrexed is the first listed.
NCT04047862 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04047862 about?
NCT04047862 is a clinical study titled "Study of Ociperlimab (BGB-A1217) in Combination With Tislelizumab in Advanced Solid Tumors". The primary objectives of this study were: to assess the safety and tolerability, to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and to determine the recommended Phase 2 dose (RP2D) of BGB-A1217 (known as ociperlimab) in combination with tislelizumab in participants...
What is the current status of trial NCT04047862?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 446 participants. The study started on 2019-08-15. Estimated completion is 2024-08-07.
What interventions are being tested in trial NCT04047862?
The interventions under investigation include: Pemetrexed (DRUG), Tislelizumab (DRUG), Paclitaxel (DRUG), Nab paclitaxel (DRUG), Ociperlimab (DRUG).
Who is sponsoring clinical trial NCT04047862?
This trial is sponsored by BeiGene, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.